Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Tuesday, September 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics Inc. announced that data from its Phase III HARMONi-GI1 trial will be presented at the ESMO 2026 Congress. The trial evaluates ivonescimab, a novel bispecific antibody, in combination with chemotherapy for advanced biliary tract cancer. This presentation highlights the potential of ivonescimab in first-line treatment settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ivonescimab shows potential as a first-in-class therapy.
  • The trial is being showcased at a prestigious symposium.
  • The study focuses on a significant cancer indication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
29.2%
average across 4 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Full Press Release Details

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O

Frequently Asked Questions

What is the HARMONi-GI1 trial about?

The HARMONi-GI1 trial evaluates ivonescimab combined with chemotherapy for advanced biliary tract cancer.

When will the HARMONi-GI1 trial data be presented?

The trial data will be showcased at the ESMO 2026 Congress from October 23-27, 2026.

Who sponsors the HARMONi-GI1 trial?

The trial is sponsored by Akeso, Inc.

What type of drug is ivonescimab?

Ivonescimab is a novel, potential first-in-class bispecific antibody.

ShareAdd on Google
Tags: SMMT Viatris Investor Conferences Healthcare ivonescimab biliary tract cancer Phase III trial ESMO 2026
Last updated: Sep 22, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~13 mo
Low dilution risk
Lead asset
IvonescimabPhase 3
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) →

Catalyst track record

+48%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →